The chart below shows how HBIO performed 10 days before and after its earnings report, based on data from the past quarters. Typically, HBIO sees a +6.05% change in stock price 10 days leading up to the earnings, and a -3.62% change 10 days following the report. On the earnings day itself, the stock moves by +0.11%. This data can give you a slight idea of what to expect for the next quarter's release.
Positive
Earnings Per Share Beat: Harvard Bioscience, Inc. reported an EPS of $0.06, beating expectations of $0.05.
Q4 Revenue Increase: Revenue in Q4 was $24.6 million, showing a 12% sequential increase from Q3.
Effective Cost Management: Adjusted operating income was $2.5 million, representing 10% of revenue, indicating effective cost management.
EBITDA Improvement in Q4: Adjusted EBITDA improved to $3 million in Q4, up from $1.3 million in Q3, reflecting revenue and margin growth.
Gross Margin Stability: Gross margin for Q4 was maintained at 57%, close to the target of 60%, despite lower revenue levels.
Positive Book-to-Bill Ratio: The company experienced a positive book-to-bill ratio, indicating strong order intake and future revenue potential.
Regional Revenue Stabilization: Sequential revenue growth was observed in the Americas (3%), Europe (28%), and Asia Pacific (8%), signaling stabilization in various markets.
Product Launch Success: The launch of new products, including the SoHo telemetry devices and VivaMARS neurobehavioral monitoring system, is generating strong interest and demand.
Electroporation System Adoption: The BTX electroporation system has been adopted by a top five pharma company, achieving a $1 million annual run rate in consumable revenue.
Market Interest in Organoid Platform: The MeshMEA organoid platform is gaining traction with early adopters like Stanford and the Mayo Clinic, indicating strong market interest.
Operating Expense Reduction: The company has successfully reduced operating expenses by $2 million or 12% year-over-year, positioning for improved profitability in 2025.
Negative
Q4 Revenue Decline: Revenue in Q4 2024 was $24.6 million, which is 13% lower than Q4 2023, indicating a decline in year-over-year performance.
Revenue Decline Analysis: Full year revenue decreased to $94 million from $112 million in the previous year, reflecting a significant drop in overall sales.
Breakeven Operating Income Challenges: Operating income was breakeven on a GAAP basis, which suggests challenges in maintaining profitability despite some cost reductions.
Decline in Adjusted EBITDA: Adjusted EBITDA for Q4 was $3 million, down from $3.6 million in Q4 2023, indicating a decline in operational efficiency year-over-year.
Cash Flow Decline: Cash flow from operations was $1.7 million in Q4, significantly lower than $4.3 million in the same quarter last year, highlighting cash flow challenges.
Net Leverage Ratio Concerns: The company was not in compliance with its net leverage ratio covenant at year-end, which raises concerns about financial stability and creditworthiness.
Revenue Dip Projection: The company expects a dip in revenue for Q1 2025, projecting between $19 million to $21 million, which reflects ongoing uncertainty in the market.
Audit and Refinancing Costs: The anticipated high professional fees related to audit and debt refinancing activities in Q1 2025 may negatively impact EBITDA, indicating potential financial strain.
Harvard Bioscience, Inc. (NASDAQ:HBIO) Q4 2024 Earnings Call Transcript
HBIO.O
3.4%